RxDoctor Payments Data

Michele Fass, MD

Family Medicine · Shepherdsville, KYNPI 1699032284

Payments from drug & device makers

$1,111in general payments, 2019–2025

Across 95 payments — averaging $11.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$204
  • Novo Nordisk$200
  • Amgen$162
  • Pfizer$144
  • Lilly USA, LLC$108
  • GSK$83
  • plus $211 from 9 others

What the payments were for

  • Food & beverage$1,08998%
  • Education$222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,111 in reported general payments places this provider in the 55th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$143,061
Medicare patients
238
Services billed
2,799

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide110$143,943
JardianceEmpagliflozin91$120,173
EliquisApixaban85$113,742
JanuviaSitagliptin Phosphate53$83,436
TrulicityDulaglutide30$66,366
FarxigaDapagliflozin Propanediol32$42,229
MounjaroTirzepatide38$41,093
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog21$33,818
Praluent PenAlirocumab32$32,154
Bydureon BciseExenatide Microspheres13$20,826
XareltoRivaroxaban13$18,933
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$18,660
Spiriva HandihalerTiotropium Bromide13$12,286
Spiriva RespimatTiotropium Bromide12$8,442
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$7,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$48$147,275117 claims
Novo NordiskOzempic$200$143,943110 claims
PfizerEliquis$144$113,74285 claims
Lilly USA, LLCTrulicity, Mounjaro$108$107,45968 claims
MerckJanuvia$11$83,43653 claims
AstraZenecaFarxiga, Symbicort$204$47,61044 claims
Johnson & JohnsonXarelto$22$18,93313 claims
GSKBreo Ellipta$83$7,57512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Shepherdsville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →